Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study
Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study
复制标题
与倾向评分匹配的rhG-CSF引发的外周血干细胞半相合移植相比，rhG-CSF动员的血液和骨髓半相合移植的临床结果得到改善：一项多中心研究
DOI：
10.1007/s11427-016-0014-8
复制
发表时间：
2016-08
影响因子：
9.1
通讯作者：
Huang Xiaojun
中科院分区：
文献类型：
--
作者：
Zhao Xiangyu;Gao Feng;Zhang Xiaohui;Wang Yu;Xu Lanping;Liu Kaiyan;Zhao Xiaosu;Chang Yingjun;Wei Han;Chen Huan;Chen Yuhong;Jiang Zhengfan;Huang Xiaojun
The effects of haploidentical rhG-CSF-mobilized blood and marrow transplantation (HBMT) on hematological malignances are well established. Previous prospective single-center studies have demonstrated better survival after HBMT versus haploidentical rhG-CSF-mobilized peripheral blood stem cell transplantation (HPBSCT) for acute leukemia (AL) not in remission (NR) or in more than the second complete remission (>CR2). To test the hypothesis that HBMT is still superior to HPBSCT for patients with AL, multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) in CR1/CR2 and for patients with chronic myeloid leukemia in the first and second chronic phase lacking a matched donor, we designed a propensity score method-based multicenter study. Hematopoietic recovery, acute graft-versus-host disease (aGVHD), and chronic GVHD were comparable between the HBMT group (n=168) and the HPBSCT group (n=42). No significant differences were found in non-relapse mortality rate (20.17%±3.58% and 27.24%±7.16%,P=0.18) or relapse rate (19.96%±3.72% and 28.49%±8.25%,P=0.32) between the HBMT group and the HPBSCT group. HBMT recipients had better overall survival (65.0%±4.2% and 54.2%±8.3%,P=0.037) and disease-free survival (59.9%±4.6% and 44.3%±8.7%,P=0.051). Multivariate analysis showed that HPBSCT was associated with poorer DFS (HR (95%CI), 1.639 (0.995–2.699),P=0.052). Our comparisons showed that HBMT was superior to HPBSCT as a post-remission treatment for patients lacking an identical donor.
登录
查看更多内容
与 G-PB 相比，在急性白血病患者进行 HLA 相合同胞移植后，使用 G-CSF 动员的血液和骨髓移植物作为干细胞来源可改善预后
影响因子：
2.1
作者：
Zhao Xiao-su;Chen Yao;Zhao Xiang-yu;Liu Dai-hong;Xu Lan-ping;Wang Yu;Han Wei;Chen Yu-hong;Chen Huan;Zhang Xiao-hui;Liu Kai-yan;Huang Xiao-jun
通讯作者：
Huang Xiao-jun
影响因子：
4.3
作者：
Apperley, Jane;Niederwieser, Dietger;Kodera, Yoshihisa
通讯作者：
Kodera, Yoshihisa
影响因子：
45.3
作者：
Aversa, F;Terenzi, A;Martelli, MF
通讯作者：
Martelli, MF
影响因子：
45.3
作者：
Bashey, Asad;Zhang, Xu;Solomon, Scott R.
通讯作者：
Solomon, Scott R.
影响因子：
4.8
作者：
Ilias Pessach;I. Resnick;A. Shimoni;Arnon Nagler
通讯作者：
Ilias Pessach;I. Resnick;A. Shimoni;Arnon Nagler